The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Cell & Gene
    • Bioprocessing
    • Drug Delivery
    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Regulation & Standards
    • Small Molecules
    • Supply Chain
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • eBooks
    • Content Hubs
Subscribe
Subscribe
The Medicine Maker / Issues / 2020 / Dec / Speeding up the Development of Purification Methods
Manufacture Bioprocessing Biopharma Sponsored

Speeding up the Development of Purification Methods

Purification experts rely on the reproducible performances and secured availability of SkillPak pre-packed columns to develop purification methods for biomolecules

12/11/2020 1 min read

Sponsored By

Share

Since the beginning of the COVID-19 pandemic, the public has realized, more than ever, how essential the biotechnology industry is in securing our civilization’s future. Downstream processing does not receive the same public attention, but none of the ongoing fights against the coronavirus would have been possible without proper purification of biomolecules. At Tosoh Bioscience, we always look at how we can enable our biopharma partners to provide safe and efficient therapies and vaccines against life-threatening diseases. Major tools to ensure fast scale-up of robust methods in the biopharma industry are pre-packed columns for early-stage development.

We launched the SkillPak® 1 and 5 mL pre-packed chromatography columns in April 2020. These columns have been welcomed by the biotech industry, as they offered a reproducible and efficient way of screening all innovative Toyopearl®, TSKgel®, and Ca++Pure-HATM process media. These columns guarantee optimal performance and can be operated with standard low- or medium-pressure liquid chromatography systems. They are reproducibly packed and take into account the varying compressibility of each resin – providing an accurate representation of conditions found in full-scale columns. In the past six months, we provided hundreds of columns to support the development of purification methods for monoclonal antibodies, antibody fragments, and oligonucleotides. Several of those projects have now entered clinical phases thanks to high throughput screening and easy scale-up.

We have developed our own solutions for the packing of small-scale columns, which not only offers the best performance for every single column, but also allows for better control of the whole supply chain. We aim to provide short delivery times for all columns, with well-planned production, strategic stocks on several continents, and integrated logistics. We have put our plan to test over the last several months, and have reached our targets day after day, despite employee lockdowns, supply route closures, and exploding demand.

If you want to see for yourself how SkillPak 1 and 5 mL pre-packed columns can help you develop better purification method faster, order a free set of columns today

Newsletters

Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Recommended

Related Content

The Mindset for Success in Biopharma's New Multipolar World
Biopharma Development & Clinical Outsourcing
The Mindset for Success in Biopharma's New Multipolar World

August 18, 2026

10 min read

From collapsing legacy models to the rise of Chinese biotech, industry leaders are being forced to rethink how drugs are developed, funded, and brought to market

Biopharma Labs Have an Integration Debt Problem
Biopharma Technology & Manufacturing
Biopharma Labs Have an Integration Debt Problem

August 17, 2026

5 min read

Biopharma labs are investing heavily in digital tools, but without trusted data architecture, each new platform can add another point of failure

Musings from The Power List: Ali Pashazadeh
Outsourcing Biopharma Business & Trends
Musings from The Power List: Ali Pashazadeh

August 7, 2026

7 min read

Ali Pashazadeh argues that management failures sink too many clinical programs – and explains why commercial discipline must start much earlier

Moving Glycosylation Control Upstream
Biopharma Interviews Technology & Manufacturing
Moving Glycosylation Control Upstream

August 6, 2026

7 min read

Samsung Biologics’ Sojeong Lee discusses why biologics developers are paying closer attention to glycosylation earlier in development.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Affiliations:

Specialties:

Areas of Expertise:

Contributions: